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Abstract
Purpose: Some [68Ga]siderophores show promise in specific and sensitive imaging of infection.
Here, we compare the in vitro and in vivo behaviour of selected Ga-68 and Zr-89 labelled
siderophores.
Procedures: Radiolabelling was performed in HEPES or sodium acetate buffer systems.
Radiochemical purity of labelled siderophores was determined using chromatography. Partition
coefficients, in vitro stability and protein binding affinities were determined. Ex vivo
biodistribution and animal imaging was studied in mice.
Results: Certain differences among studied siderophores were observed in labelling efficiency.
Protein binding and stability tests showed highest stabilities and lowest protein binding affinities
for Ga-68 and [89Zr]triacetylfusarinine C (TAFC). All studied Ga-68 and [89Zr]siderophores
exhibited a similar biodistribution and pharmacokinetics in mice with the exception of
[89Zr]ferrioxamine E (FOXE).
Conclusions: Zr-89 and [68Ga]siderophores showed analogous in vitro and in vivo behaviour.
Tested [89Zr]siderophores could be applied for longitudinal positron emission tomography (PET)
studies of fungal infections and especially TAFC for the development of novel bioconjugates.
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Introduction
Siderophores are high affinity, iron-selective chelators
produced by almost all bacteria, fungi and some plants [1,
2]. They serve as carrier molecules transporting iron across
the microbial cell membranes, thus representing an excellent
source of iron for many microorganisms. Iron is an essential
nutrient for all cells and plays an important role also in
microbial virulence [3]. Under iron-restricted conditions,
some microorganisms secrete siderophores into the environ-
ment where they collect iron from various sources and
deliver it into the producing organism [4]. In some species,
specialized siderophores are synthesized, which are not
excreted and serve as a unique iron storage form.
Siderophores and their analogues have found wide applica-
tion in agriculture and in medicine [5]. In medicine,
siderophores have shown potential in applications like
selective drug delivery; treatment of diseases, e.g.,
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thalassemia, malaria and sickle cell disease; cancer therapy
and imaging cancer and infection [5, 6].
Some Gallium-68 (Ga-68) labelled siderophores have
demonstrated their use as specific agents for imaging
Aspergillus infection [7]. Gallium (Ga3+; ionic
radius=62 pm) and iron (Fe3+; ionic radius=64 pm) are
structurally similar and have similar coordination properties.
Ga-siderophore complexes are recognized by cellular trans-
porters and receptors on bacterial cells allowing the complex
to enter inside the microbial cell. Ga-68 is a radioactive
isotope of gallium and has in recent years gained a lot of
attention in the field of nuclear medicine for molecular
imaging using positron emission tomography (PET) [8, 9]. It
is a short-lived positron emitter (half-life=67.7 min) that can
be produced from a long shelf-life and cost-effective [68Ge]/
[68Ga] generator system. The relatively short half-life of Ga-
68 can be a limitation especially in longitudinal studies. This
deficit can be resolved using longer-lived positron-emitting
radionuclides such as Cu-64, I-124, Y-86, Nb-90 or Zr-89
[10].
The interest in Zirconium-89 (Zr-89) has increased over
the last years as it displays almost ideal properties allowing
imaging of biological processes at late time-points after the
tracer application [11]. Even though Zr-89 has comparably
low positron abundance and due to the long half-life results
in higher radiation dose, it allows long-term follow-up
especially of slowly accumulating biomolecules such as
antibodies, nanoparticles and other large biomolecules both
for preclinical and clinical applications, thereby
complementing Ga-68 with its limitations of a very short
half-life. Zr-89 can be produced in a cyclotron in large
quantities and at high radionuclidic purity (99.99 %) [12]. It
decays with a half-life of 78.4 h via both positron emission
(23 %) and electron capture (77 %). The relatively low
positron energy of 396.9 keV results in high image
resolution [13]. The preferred oxidation state of zirconium
is +4 with an ionic radius of 72 pm, also similar to the ferric
iron.
In our previous studies, we have shown that different
siderophores can be labelled with Ga-68 [14]. We have also
demonstrated that [68Ga]triacetylfusarinine C (TAFC) and
[68Ga]ferrioxamine E (FOXE) are able to detect Aspergillus
fumigatus infection in a rat infection model using PET
imaging [7, 15] and that [68Ga]TAFC is highly specific to
A. fumigatus in vitro [16]. Desferrioxamine B (FOXB), a
hydroxamate siderophore, is the most commonly used
bifunctional chelator for coordination of Zr-894+. Several
preclinical proof-of-principle studies have been conducted
using FOXB to label antibodies with Zr-89, but the in vivo
stability of this complex remains an issue [17]. Our aim in
this study was to evaluate the potential of alternative
siderophores for radiolabelling with Zr-89 and as imaging
agents for Aspergillus infections. We also wanted to
investigate any potential differences between the resulting
Zr-89 complexes and the respective Ga-68 complexes; the
differences in charge (Zr4+ vs. Ga3+) could impact complex
stability and other properties such as lipophilicity. We have
investigated this issue and report here the in vitro and in vivo




All commercially available reagents were used as supplied with no
further purification. Siderophores were purchased from EMC
microcollections GmbH (Tubingen, Germany). [68Ga]Cl3 was
eluted from a [68Ge]/[68Ga] generator (Eckert & Ziegler Eurotope
GmbH, Berlin, Germany) with 0.1 N HCl using the fractionated
elution approach. Zr-89 in 1 M oxalic acid was produced by the BV
Cyclotron VU (Amsterdam, The Netherlands) and distributed by
PerkinElmer (Boston, USA).
Siderophores Radiolabelling and Quality Control
Ga-68 labelled siderophores were prepared as previously described
[14]. Radiolabelling of siderophores with Zr-89 was performed
using 9–11 μl of Zr-89 in 1 M oxalic acid (7–12 MBq) and
neutralized with 10 μl 1 M Na2CO3, then mixed with 100 μl of
HEPES buffer (0.5 M, pH=7) and 20–50 μl of an aqueous solution
of desferrisiderophores (1 μg/μl). The reaction mixture was allowed
to react at room temperature (RT) for 90 min. Alternatively, direct
incubation of 9–11 μl Zr-89 in 1 M oxalic acid with 30–40 μl of
sodium acetate (155 mg/ml in water) mixed with 20–50 μl of
desferrisiderophores dissolved in water (1 μg/μl) was performed.
Incubation times (15–20 min) and temperature (RT or 80 °C) were
varied. Radiochemical purity (RCP) of labelled siderophores was
determined on reverse-phase high-performance liquid chromatog-
raphy (RP-HPLC) using a gradient system as described previously
[15]. [89Zr]siderophores were additionally analysed by thin-layer
chromatography (ITLC-SG/50 mM EDTA), in which
[89Zr]siderophores remained at the origin and unbound Zr-89
moved with the solvent front.
In Vitro Characterization of Radiolabelled
Siderophores
Partition Coefficient DeterminationRadiolabelled siderophore
in 0.5 ml phosphate-buffered saline (PBS) pH=7.4 was added to
0.5 ml octanol and the mixture was vigorously vortexed for 15 min.
The aqueous and organic solvents were separated by centrifugation
and 50 μl aliquots of both layers were collected and measured in
the automatic gamma counter (WIZARD2; PerkinElmer, Waltham,
USA). Log P values were calculated from obtained data (mean of
n=6).
Protein BindingProtein binding studies were performed by
incubating radiolabelled siderophore (1–2 μg/150 μl) in fresh
human serum (850 μl) and in PBS (850 μl) (control) at 37 °C for
various time points (30, 60 and 120 min for [68Ga]siderophores and
1, 4 and 24 h for [89Zr]siderophores). After incubation, 25 μl of the
sample was separated by size-exclusion chromatography
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(MicroSpin™ G-50 Columns; Sephadex G-50 (GE Healthcare,
Buckinghamshire, UK)) by centrifugation at 2000×g for 2 min.
Protein binding of radiolabelled siderophores was determined by
measuring the activity distributed between the column (non protein-
bound) and the eluate (protein-bound) using the automatic gamma
counter.
Stability StudiesThe in vitro stability of radiolabelled
siderophores (3–6 μg/100 μl) was tested in fresh human serum
(300 μl) and a 6 mM solution of diethylenetriaminepentaacetic acid
(DTPA) pH=7 (100 μl) at 37 °C at several time points (30, 60 and
120 min for [68Ga]siderophores and 1, 4 and 24 h for
[89Zr]siderophores). After incubation, human serum samples were
precipitated with acetonitrile or ethanol, centrifuged (2200×g,
3 min) and the supernatant analyzed. Degradation of the
radiolabelled siderophore complexes was evaluated by RP-HPLC.
Samples of the DTPA solutions were directly injected onto the
HPLC.
Animal Experiments
All animal experiments were conducted in accordance with
regulations and guidelines of the Czech Animal Protection Act
(No. 246/1992), and with the approval of the Czech Ministry of
Education Youth and Sports (MSMT-18933/2013-1), and the
institutional Animal Welfare Committee of the Faculty of Medicine
and Dentistry of Palacky University in Olomouc. The studies were
performed using female Balb/c mice (Anlab, Prague,
Czech Republic).
Biodistribution in Balb/c Mice
Biodistibution of radiolabelled siderophores was studied in female
Balb/c mice (8 weeks old). Ga-68 and Zr-89 labelled siderophores
(1–2 MBq/mouse, corresponding to 0.1–0.2 μg of siderophore per
mouse) were injected retro-orbitally (r.o.). Animals were sacrificed
by cervical dislocation 30 and 90 min post-injection (p.i.). Organs
and tissues (blood, spleen, pancreas, stomach, intestine, kidneys,
liver, heart, lung, muscle and femur) were removed and weighed.
The amount of radioactivity in the samples was measured in an
automatic gamma counter. Results were expressed as percentage of
injected dose per gram organ (%ID/g).
PET Imaging of Radiolabelled Siderophores in
Balb/c Mice
PET and computed tomography (CT) images were acquired with an
Albira PET/SPECT/CT small animal imaging system (Bruker
Biospin Corporation, Woodbridge, CT, USA). Female Balb/c mice
were r.o. injected with radiolabelled siderophores in a dose of 5–
10 MBq corresponding to 0.5–1 μg of siderophore per mouse.
Animals were anaesthetized with isoflurane (FORANE, Abbott
Laboratories, Abbott Park, IL, USA) (2 % flow rate) and positioned
prone head first in the Albira system before the start of imaging.
Fig. 1 Structures of studied siderophores.
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Static PET/CT imaging was carried out 5, 30 and 90 min p.i. for
both Ga-68 and Zr-89 labelled siderophores. Animals injected with
[89Zr]siderophores were also imaged 4 h p.i. A 5-min PET scan
(axial FOV 148 mm) was performed, followed by a CT scan (axial
FOV 65 mm, 45 kVp, 400 μA, at 600 projections). Dynamic
imaging was carried out immediately after the injection of
radiolabelled siderophore for 90 min (5 min PET scan per frame).
Scans were reconstructed with the Albira software (Bruker Biospin
Corporation, Woodbridge, CT, USA) using the maximum likeli-
hood expectation maximization (MLEM) and filtered
backprojection (FBP) algorithms. After reconstruction, acquired
data was viewed and analyzed with PMOD software (PMOD
Technologies Ltd., Zurich, Switzerland). 3D images were obtained
using VolView software (Kitware, Clifton Park, NY, USA).
Animal imaging was performed for all studied siderophores except
for ferrichrome A (FCHA).
Results
Radiochemistry
The labelling conditions as well as labelling efficiency were
slightly different for studied desferrisiderophores.
Desferritriacetylfusarinine C (TAFC) and desferriferichrome
A (FCHA) were labelled with Ga-68 in sodium acetate
buffer at room temperature for 15 min with an RCP greater
than 98 %. Radiolabelling of desferrioxamine E (FOXE) and
desferrioxamine B (FOXB) with Ga-68 was performed in
sodium acetate buffer at 80 °C for 20 min with an RCP
greater than 98 %. Zr-89 labelling of all studied siderophores
using Na2CO3 for neutralization followed by incubation with
the siderophore in HEPES buffer (pH=7) required incubation
times of more than 90 min at RT with the RCP greater than
98 %. Interestingly, direct incubation of [89Zr]oxalate with
the corresponding siderophore in sodium acetate buffer at
80 °C for 20 min resulted in equivalent results with a
radiochemical purity of not less than 90 % as determined by
HPLC (Suppl Fig. 1) and ITLC-SG. This was considered as
sufficient for this initial evaluation of [89Zr]siderophores,
and the methods using sodium acetate buffer for Ga-68 as
well as for Zr-89 labelling of siderophores were used for
further in vitro and in vivo experiments.
In Vitro Characterization
All studied siderophores showed hydrophilic properties with
partition coefficients (log P) ranging from −1.65 to −3.56.
FOXE and FCHA displayed very similar log P values for
both Ga-68 and Zr-89 complexes, while TAFC and FOXB
displayed more lipophilic character when labelled with Zr-
89. Protein binding values did not exceed 11 % for
[68Ga]siderophores (incubation time 120 min), whereas
[89Zr]FOXE and [89Zr]FCHA showed 16.6 and 31.1 % of
protein binding after 24-h incubation period. All the
[68Ga]siderophores were stable in vitro, with the exception
of [68Ga]FOXB (Table 1). The stability studies of
[89Zr]siderophores (Table 2) displayed some differences
compared to [68Ga]siderophores. In particular, [89Zr]FCHA
was less stable as compared to its Ga-68 labelled counterpart
whereas [89Zr]FOXB revealed higher stability in all exam-
ined media.
Ex Vivo Biodistribution in Balb/c Mice
Ga-68 and Zr-89 labelled TAFC, FCHA and FOXB showed
virtually identical ex vivo biodistribution in Balb/c mice. All
six compounds were rapidly excreted via the renal system
and showed minimal retention in blood and the various
organs. [68Ga]FOXE revealed similar biodistribution with
slightly higher radioactivity values in gastrointestinal tract
compared to the other radiolabelled siderophores, whereas
[89Zr]FOXE showed significantly higher radioactivity accu-
mulation in the intestines and liver. In all cases,
[89Zr]siderophores displayed slightly higher bone uptake
compared to their Ga-68 labelled counterparts, but always
lower than 1 %ID/g, whereas there was a trend of higher
blood activity for Ga-68 vs. [89Zr]compounds, both
Table 1. In vitro characterization of studied Ga-68 labelled siderophores. Log P, protein binding (expressed as % of protein bound activity of the total activity
used) and stability (in human serum and 6 mM DTPA) of [68Ga]TAFC, [68Ga]FOXE, [68Ga]FCHA and [68Ga]FOXB
[68Ga]siderophore Log P
(mean±SD, n=6)






[68Ga]TAFC −2.59±0.15 30 0.47 99.9 85.0
60 0.76 99.9 84.7
120 1.21 99.9 81.8
[68Ga]FOXE −1.65±0.03 30 0.27 99.9 94.3
60 0.24 99.9 93.8
120 0.53 99.9 93.2
[68Ga]FCHA −3.24±0.07 30 5.12 97.4 97.7
60 6.98 97.8 95.7
120 4.21 98.5 92.3
[68Ga]FOXB −3.56±0.17 30 7.67 74.1 60.1
60 10.29 72.0 54.5
120 10.83 75.4 52.9
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indicating the behaviour of the free radionuclides. Ex vivo
biodistribution data are presented in Fig. 2.
Small Animal PET Imaging
MicroPET imaging of Balb/c mice injected with Ga-68
and Zr-89 labelled TAFC and FOXB showed rapid
clearance from the bloodstream with the major excretion
route via kidneys. Both pairs of radiolabelled
siderophores displayed very similar kinetics and
biodistribution (Figs. 3 and 4). Significantly different
in vivo behaviour was observed for the [68Ga]/
[89Zr]FOXE pair. [68Ga]FOXE was quickly eliminated
mainly via the kidneys with certain part of radioactivity
excreted via the gastrointestinal tract, while [89Zr]FOXE
revealed much slower kinetics and significant
hepatobiliary elimination. Animal imaging data confirmed
and supplemented the data from ex vivo biodistribution
studies. The representative imaging data is presented in
Figs. 3 and 4.
Discussion
Until recently, the majority of preclinical and clinical
research has focused on the development of PET
radiopharmaceuticals using conventional PET radionu-
clides such as C-11, N-13, O-15 and F-18 [18]. This has
changed with the increased availability and production
of non-conventional positron-emitting radionuclides such
as Cu-64, Ga-68, Y-86, Zr-89 and I-124. Recently, Ga-
68 and Zr-89 have generated significant interest in the
nuclear medicine community with a concomitant in-
crease in the use of Ga-68 labelled peptides for PET
imaging of neuroendocrine tumours and Zr-89
imunoPET [8, 19].
The radiolabelling of biomolecules with Zr-89 is
usually performed by the desferrioxamine B (FOXB)
chelator, commercially available as Desferal. FOXB is a
hexadentate siderophore containing three hydroxamate
groups for chelating metals and a primary amine
functional group for conjugation to a biomolecule. It is
a chelating agent for several metal ions besides Zr-89
[20]. Zr-89 radiolabelling of biomolecules using the
FOXB chelator has shown that the in vivo stability of
this complex remains an issue. This instability has been
observed in several preclinical studies with uptake of Zr-
89 in bones [21, 22]. While many investigators have
focused on the modification of the linkage between the
FOXB and the biomolecule [23, 24], others have
attempted to improve the chelator itself [25–29]. Despite
these attempts, a novel high-stability Zr4+ ligand which
would minimize the uptake of liberated Zr4+ in the bone
and other non-targeted tissue is warranted.
In this study, we have investigated the in vitro and
in vivo behaviour of selected hydroxamate siderophores
labelled with Zr-89 to evaluate their potential to be used
as novel Zr-89 chelators and to compare their in vitro
and in vivo properties with their Ga-68 labelled counter-
parts. We note that studied siderophores are only
hexadentate ligands and cannot coordinatively saturate
Zr4+ that can bind up to eight ligand atoms. Therefore, it
is to be expected that the additional positive charge of
Zr4+ will have a pronounced effect on chemical and
biological properties of small chelators such as
siderophores. However, the complexation of Zr4+ is
affected not only by number of coordinating atoms but
also by linear vs. cyclic character, optimal ring size and
appropriate geometry of the ligand [26].
Triacetylfusarinine C (TAFC) and ferrioxamine E
(FOXE) are macrocyclic hydroxamate siderophores with
the ring size of 35 (TAFC) and 33 (FOXE) atoms, which
is deemed to be in the appropriate range for Zr4+
chelation to preserve the optimal spatial orientation
[25]. These siderophores were chosen due to their
successful application as Ga-68 labelled tracers in the
imaging of Aspergillus infection in rats [7]. We aimed to
further test the ability of Zr-89 to label these promising
Table 2. In vitro characterization of studied Zr-89 labelled siderophores. Log P, protein binding (expressed as % of protein bound activity of the total activity
used) and stability (in human serum and 6 mM DTPA) of [89Zr]TAFC, [89Zr]FOXE, [89Zr]FCHA and [89Zr]FOXB
[89Zr]siderophore Log P
(mean±SD, n=6)






[89Zr]TAFC −1.95±0.03 1 0.99 98.08 99.51
4 0.34 98.72 99.50
24 1.37 98.50 99.50
[89Zr]FOXE −1.91±0.04 1 3.27 98.07 99.70
4 5.86 99.70 99.50
24 16.59 98.34 99.70
[89Zr]FCHA −3.28±0.37 1 2.70 92.76 68.70
4 6.24 85.42 65.27
24 31.05 77.38 54.22
[89Zr]FOXB −3.01±0.07 1 1.63 99.61 91.56
4 2.05 99.70 90.39
24 1.84 99.53 87.10
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infection imaging agents in order to enlarge their
imaging time frame for imaging Aspergillus infection,
e.g., for treatment monitoring. Ferrichrome A (FCHA)
and FOXB are representatives of linear hydroxamate
siderophores. FOXB was selected as a standard chelating
agent used in nuclear medicine for Zr-89 labelling.
Fig. 2 Ex vivo biodistribution of studied radiolabelled siderophores in Balb/c mice 30 and 90 min p.i. Data are presented as
percentage of injected dose per gram organ (%ID/g±SD; n=3).
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All siderophores that were tested could be labelled to
near-completeness with both Ga-68 and Zr-89 using
established labelling protocols. Both Ga-68 and Zr-89
labelled siderophores showed hydrophilic properties with
[89Zr]siderophores having a tendency to be slightly more
lipophilic. This is rather surprising, as the binding of Ga3+
results in a neutral molecule, whereas Zr4+ introduces an
additional positive charge. Significant differences among
studied siderophores were observed mainly in protein
binding and in vitro stability. [68Ga]TAFC, [68Ga]FOXE
and [68Ga]FCHA displayed identical or lesser protein
binding abilities than their Zr-89 labelled counterparts, while
[68Ga]FOXB revealed higher protein binding values in
comparison with [89Zr]FOXB. It could be speculated that
the change of cation in the complex with difference in
charge leads to a more amphiphilic character resulting in
higher binding to plasma proteins or possibly phospholipids,
but more experimental data would be required to support
such a hypothesis. Ga-68 labelled cyclic hydroxamate
siderophores (TAFC and FOXE) and [68Ga]FCHA were
very stable in all tested media, whereas [68Ga]FOXB
showed pronounced in vitro instability. The in vitro stability
of studied [89Zr]siderophores was different in some aspects.
For instance, [89Zr]FOXB displayed a much higher in vitro
stability than [68Ga]FOXB. Ex vivo biodistribution and small
animal imaging of all Ga-68 and Zr-89 labelled siderophores
injected into Balb/c mice displayed similar pharmacokinetics
and minimal accumulation of radioactivity in blood and
other organs and tissues with the exception of [89Zr]FOXE,
which caused significant retention of radioactivity in the
gastrointestinal tract. In all cases, [89Zr]siderophores
displayed slightly higher (90 min p.i.), but still very low,
retention of radioactivity in bones, indicating favourable
in vivo stability in the studied time intervals. The differences
in the behaviour of Ga-68 and the corresponding
[89Zr]siderophores could be explained by the different
charge of the two radio-metal ions, resulting in a positively
charged complex for hydroxamate coordinations for Zr in
contrast to a neutral overall charge in the case of Ga. Even
though there was no obvious instability of Zr-89 com-
pounds, further investigations are required especially in the
view of a higher stability of Zr-complexes by using
octacoordinating ligands [25, 28].
The overall comparable properties of Ga-68 and Zr-89
labelled siderophores (despite the differences of Ga and Zr
in terms of charge, coordination chemistry and ionic radius)
warrant further investigation of the targeting behaviour of
Zr-89 labelled siderophores. This is of high interest in the
application of the radiolabelled siderophores in the imaging
of infection, in particular, infection by invasive fungal
pathogens. The preclinical monitoring of therapy could
benefit from a radionuclide that has a longer half-life, as it
Fig. 3 3D volume rendered images of static μPET/CT imaging of [68Ga]siderophores (a—TAFC=1, FOXE=2, FOXB=3) and
[89Zr]siderophores (b—TAFC=1, FOXE=2, FOXB=3) 90 min p.i. (supine position; injected dose, 5–10MBq; anaesthesia, 2% isoflurane;
scan duration, 5 min PET scan followed by 20 min CT scan; B—bladder, G—gastrointestinal tract, GB—gall bladder, K—kidney).
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would enable longer imaging times (from minutes to days).
However, there is no data available so far that proves that
[89Zr]siderophores such as TAFC are recognized by the
specific transporters of microorganisms in the same way as
their Ga-68 labelled counterparts [7, 15]. Further studies in
this respect are ongoing. The other application could lie in
the development of novel, more stable [89Zr]bioconjugates,
coupling siderophores to, e.g., receptor of antigen targeting
sequences. Here, the difference of Zr-89 vs. Ga-68 labelling
will not result in a difference in targeting properties, but may
result in different pharmacokinetics due to changes in charge
and resulting lipophilicity. In this regard, preliminary studies
of fusarinine C (FSC)-based bioconjugates that have been
described recently for Ga-68 labelling [30] and Zr-89
labelling [31] showed excellent in vivo stabilities and tumour
targeting.
Conclusion
We have shown in this study that a variety of siderophores
can be labelled with Ga-68 and Zr-89. Ga-68 and
[89Zr]siderophores displayed analogous, but not fully iden-
tical in vitro and in vivo behaviour. Ga-683+ seems to be the
more suitable radionuclide for labelling of hexadentate
hydroxamate siderophores. Nevertheless, [89Zr]TAFC
showed favourable properties for potential longitudinal
Aspergillus infection imaging using the animal model from
our previous studies, and also availability as a model
structure for preparation of novel bioconjugates.
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